A New Type of Blood Pressure Drug That Boosts Natriuretic Peptides While Blocking Angiotensin
Vasopeptidase inhibitors simultaneously block two key enzymes — ACE and neutral endopeptidase — boosting protective natriuretic peptides while reducing harmful angiotensin, offering a dual approach to blood pressure control.
Quick Facts
What This Study Found
Vasopeptidase inhibitors simultaneously increase natriuretic peptide levels (by blocking NEP) and decrease angiotensin II (by blocking ACE), producing superior blood pressure reduction compared to ACE inhibition alone.
Key Numbers
How They Did This
Review article covering the pharmacological rationale, preclinical data, and early clinical trial results of vasopeptidase inhibitors (dual ACE/NEP inhibitors) for cardiovascular therapy.
Why This Research Matters
Combining two mechanisms of blood pressure control in one molecule is more effective and simpler than taking two separate drugs. This concept influenced the development of sacubitril/valsartan (Entresto), now a standard heart failure treatment.
The Bigger Picture
This concept of boosting the body's protective peptides while blocking harmful ones transformed cardiovascular drug development. It led directly to the neprilysin inhibitor concept behind sacubitril/valsartan, which has saved countless lives in heart failure.
What This Study Doesn't Tell Us
Review of early-stage clinical data. First-generation vasopeptidase inhibitors (omapatrilat) were later limited by angioedema risk. The concept was eventually refined in a different drug class.
Questions This Raises
- ?Can the angioedema risk be eliminated from dual inhibitors?
- ?Would vasopeptidase inhibition benefit other conditions beyond hypertension?
- ?Are there additional protective peptides that could be boosted through enzyme inhibition?
Trust & Context
- Key Stat:
- Dual mechanism One molecule simultaneously increases protective natriuretic peptides and decreases harmful angiotensin II for superior blood pressure control
- Evidence Grade:
- Moderate evidence from a review of preclinical and early clinical data for a novel pharmacological concept.
- Study Age:
- Published in 1999. While first-generation vasopeptidase inhibitors had safety issues, this concept evolved into sacubitril/valsartan (Entresto), now a cornerstone of heart failure treatment.
- Original Title:
- Vasopeptidase inhibition: a new concept in blood pressure management.
- Published In:
- Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 17(1), S37-43 (1999)
- Authors:
- Burnett, J C(6)
- Database ID:
- RPEP-00515
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is vasopeptidase inhibition?
It means blocking two enzymes at once: one that produces blood vessel-constricting angiotensin, and one that destroys blood vessel-relaxing natriuretic peptides. The result is more relaxed blood vessels from two directions.
Are these drugs used today?
The first vasopeptidase inhibitors had side effect issues, but the concept evolved into sacubitril/valsartan (Entresto), which combines natriuretic peptide boosting with angiotensin blocking and is now a standard heart failure treatment.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00515APA
Burnett, J C. (1999). Vasopeptidase inhibition: a new concept in blood pressure management.. Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 17(1), S37-43.
MLA
Burnett, J C. "Vasopeptidase inhibition: a new concept in blood pressure management.." Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1999.
RethinkPeptides
RethinkPeptides Research Database. "Vasopeptidase inhibition: a new concept in blood pressure ma..." RPEP-00515. Retrieved from https://rethinkpeptides.com/research/burnett-1999-vasopeptidase-inhibition-a-new
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.